APA (7th ed.) Citation

KR, P., PL, N., JA, P., Y, L., AD, P., DE, S., . . . FY, F. (2026). Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Phase 3 Trials. European urology oncology, 9(2), 413. https://doi.org/10.1016/j.euo.2024.10.017

Chicago Style (17th ed.) Citation

KR, Patel, et al. "Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Phase 3 Trials." European Urology Oncology 9, no. 2 (2026): 413. https://doi.org/10.1016/j.euo.2024.10.017.

MLA (9th ed.) Citation

KR, Patel, et al. "Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Phase 3 Trials." European Urology Oncology, vol. 9, no. 2, 2026, p. 413, https://doi.org/10.1016/j.euo.2024.10.017.